Evidence map›Paper›PMID 42819957›Full record

ArticleJACS Au2026

All-Hydrocarbon Macrocycle Enables Highly Potent Th1-Biased NKT Cell Agonists for Immunotherapy.

Qian-Nan Sun, Yu Wen, Ye-Hui Wu, De-Xiang Mei, Zheng-Qin Liu, Xiao-Ya An, Jun Guo

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JACS Au, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Qian-Nan SunInternational Joint Research Center for Intelligent Biosensing Technology and Health, National Key Laboratory of Green Pesticide, College of Chemistry, Central China Normal University, Wuhan 430079, China.
Yu WenDepartment of Pharmacology, Health Science Center, Yangtze University, Jingzhou 434023, China.
Ye-Hui WuInternational Joint Research Center for Intelligent Biosensing Technology and Health, National Key Laboratory of Green Pesticide, College of Chemistry, Central China Normal University, Wuhan 430079, China.
De-Xiang MeiInternational Joint Research Center for Intelligent Biosensing Technology and Health, National Key Laboratory of Green Pesticide, College of Chemistry, Central China Normal University, Wuhan 430079, China.
Zheng-Qin LiuInternational Joint Research Center for Intelligent Biosensing Technology and Health, National Key Laboratory of Green Pesticide, College of Chemistry, Central China Normal University, Wuhan 430079, China.
Xiao-Ya AnInternational Joint Research Center for Intelligent Biosensing Technology and Health, National Key Laboratory of Green Pesticide, College of Chemistry, Central China Normal University, Wuhan 430079, China.
Jun GuoInternational Joint Research Center for Intelligent Biosensing Technology and Health, National Key Laboratory of Green Pesticide, College of Chemistry, Central China Normal University, Wuhan 430079, China.ORCID https://orcid.org/0000-0002-2097-5054

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immunotherapy has markedly advanced cancer treatment, with Th1-biased natural killer T (NKT) cell agonists emerging as promising candidates owing to their ability to induce potent antitumor immunity. However, α-galactosylceramide (αGalCer), the prototypical NKT agonist, induces mixed Th1/Th2 responses with antagonistic cytokine effects, limiting therapeutic selectivity. The development of potent immunostimulatory agents promote Th1 polarization remains a major challenge. Herein, we convert the linear aliphatic chain of αGalCer into a conformationally constrained all-hydrocarbon macrocyclic scaffold, establishing the first report of a purely hydrocarbon macrocycle pharmacophore. Guided by the structural architecture of the CD1d antigen-binding groove, this design preorganizes the aliphatic chain to optimize A' pocket occupancy, reduce entropic penalties, and enhance binding stability. αGalCer macrocyclized (

Indexed as

conformational constraintimmunotherapymacrocycleNKT cell agonistvaccine adjuvant

Identifiers

PMID42819957
PMCPMC13625578

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.